September 26, 2011: New Data Inspire Global Experts to Call for Improved Education, Awareness and Support for Head and Neck Cancer Patients - June 09, 2011: Merck Serono: Patient Enrollment Completed for Cilengitide’s Pivotal PhaseIII Trial CENTRIC - June 04, 2011: ASCO 2011: Erbitux Increased Overall Survival by 5.1 Months in Patients - April 19, 2011: Publication of Survival Benefit in Leading Journal Emphasizes Importance of Erbitux in 1st Line mCRC